InvestSMART

Cogstate Limited (ASX:CGS)

ALERT: Price-sensitive ASX Announcement for CGS
Current share price for CGS : $3.090 0.3 (10.75%)+
Announcement
Release
18 Aug 2026 8:13AM
Price at Release
$2.790
Full Release
download
Summary
Cogstate Limited reported a record financial performance for FY26, driven by substantial growth in CNS clinical trials. The company achieved record sales contracts of $89 million, marking a 116% increase from the previous year, with revenues reaching $60.9 million. EBITDA stood at $18.3 million with a 30% margin, highlighting effective cost management and the scalability of its clinical trial solutions. The company focused on technology and AI-driven innovations, enhancing its operating platform to support scalability and quality improvements. Cash flows remained strong, enabling strategic investments and shareholder returns through dividends and share buy-backs. The company enters FY27 with a strong contracted revenue base, aiming to further leverage technology investments for continued growth.
Key Points
  • Record sales contracts of $89 million in FY26, up 116%.
  • Group revenue increased to $60.9 million.
  • EBITDA of $18.3 million with a 30% margin.
  • Net profit before tax increased to $16.1 million.
  • Continued investment in AI-enabled workflows.
  • Strong operating cash flow and cash balance.
  • Dividend of A$0.04 per share declared.
  • Strategic partnerships enhance sales opportunities.
  • 172 active trials as of June 2026.
  • FY27 outlook includes investment in technology-enabled scale.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.